Plain-English translation of NCT06706284 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing semaglutide (a medication already used for weight loss and blood sugar control) in people who have both spinal cord injury and type 2 diabetes. Researchers want to see if this medication can help improve blood sugar levels and support weight loss in this specific group of patients. You would receive either the real medication or a placebo injection once a week for 24 weeks.
People with spinal cord injuries often struggle with weight gain and blood sugar control because of reduced mobility and changes in how their bodies work. This medication is effective for weight loss and diabetes in other patients, but it hasn't been thoroughly studied in people with spinal cord injuries, so researchers want to see if it works well and is safe for this group.
You likely qualify if…
You likely don't qualify if…
You would come in for 7–9 in-person visits over 24 weeks, starting with baseline health checks and two special tests (a meal test and an insulin sensitivity test) to measure how your body responds. Then you would be randomly assigned to receive either weekly injections of the medication or placebo injections that you give yourself at home. During the 24 weeks, you'll receive 9–10 phone calls to check on your progress and return for two brief check-in visits. At the end, you'll repeat the baseline tests to see how the treatment affected your blood sugar and weight.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States